Genscript Biotech Corporation (GNNSF)

1.4700 0.0000 (0.00%) At close: 10:09AM EDT

Genscript Biotech Corporation

Jiangning Science Park
No. 28, Yongxi Road Jiangning District
Nanjing 211100
China
86 25 5889 7288
https://www.genscript.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6,937

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jiange Meng	Executive Chairman	693k	N/A	1968
Ms. Weihui Shao	CEO & COO	N/A	N/A	1980
Ms. Ye Wang M.S.	Co-Founder, President & Executive Director	461k	N/A	1968
Mr. Shiniu Wei	Chief Financial Officer	N/A	N/A	1979
Dr. Li Zhu Ph.D.	Chief Strategy Officer & Executive Director	280k	N/A	1950

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation. The Biologics Development Services segment offers end-to-end service offerings to biologics development and manufacturing for biopharma and biotech partners, as well as therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor CAR-T cell therapies for the treatment of liquid and solid tumors. It has a strategic partnership with Multiply Labs for automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Corporate governance

Genscript Biotech Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.